Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 671 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: IL-2 Clear all
Recruiting Phase 1Phase 2 Interventional

Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease

NCT07651319
View directory record Official record
Conditions
Alzheimer Dementia (AD)
Interventions
IL-2 (Aldesleukin), Semaglutide Plus IL-2, Placebo
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
50 Years to 86 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 19, 2026, 4:19 PM EDT
Completed Phase 2 Interventional

A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia

NCT00001567
View directory record Official record
Conditions
Hairy Cell Leukemia
Interventions
Roferon-A
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 19, 2026, 4:19 PM EDT
Completed Phase 1 Interventional

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

NCT05628883
View directory record Official record
Conditions
Metastatic Melanoma, Unresectable Melanoma, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, Ocular Melanoma, Uveal Melanoma, Iris Melanoma, Conjunctival Melanoma, Non-Cutaneous Melanoma
Interventions
TBio-4101, Cyclophosphamide, Fludarabine, Interleukin-2
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 19, 2026, 4:19 PM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)

NCT05092360
View directory record Official record
Conditions
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
Nemvaleukin and Pembrolizumab Combination, Pembrolizumab, Nemvaleukin, Pegylated Liposomal Doxorubicin (PLD), Paclitaxel, Topotecan, Gemcitabine
Biological · Drug
Lead sponsor
Mural Oncology, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
37
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 19, 2026, 4:19 PM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia

NCT00002925
View directory record Official record
Conditions
Leukemia
Interventions
ara-C, Daunorubicin, Etoposide, PSC-833, Aldesleukin
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years to 59 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2010
U.S. locations
33
States / cities
La Jolla, California • San Francisco, California • Wilmington, Delaware + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2012 · Synced Oct 19, 2026, 4:19 PM EDT
Completed Phase 1 Interventional

T1DM Immunotherapy Using Polyclonal Tregs + IL-2

NCT02772679
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
PolyTregs+IL-2
Biological
Lead sponsor
Jeffrey Bluestone
Other
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
San Francisco, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 19, 2026, 4:19 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus

NCT01453140
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Cyclophosphamide and Sirolimus, Low dose IL-2 with Cytoxan + Sirolimus, Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus, Low dose IL-2, Vidaza, Cytoxan & Sirolimus
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 19, 2026, 4:19 PM EDT
Completed Phase 2 Interventional

A Phase I/II Study of the Combination of Azidothymidine and Interleukin-2 (IL-2) in the Treatment of HIV-Infected Patients

NCT00001282
View directory record Official record
Conditions
HIV Infection
Interventions
Zidovudine (AZT) & Interleukin-2 (IL2)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 19, 2026, 4:19 PM EDT
Not listed Phase 1 Interventional

Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

NCT03068624
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma
Interventions
Aldesleukin, Autologous CD8+ SLC45A2-specific T Lymphocytes, Cyclophosphamide, Ipilimumab
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Oct 19, 2026, 4:19 PM EDT
Active, not recruiting Phase 2 Interventional

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

NCT00338377
View directory record Official record
Conditions
Melanoma
Interventions
Dendritic Cell Immunization, Cyclophosphamide, Fludarabine, T-Cells, Interleukin-2, Mesna, Intrathecal T-Cells, Intrathecal Interleukin-2
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
1,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 19, 2026, 4:19 PM EDT
Active, not recruiting Phase 2 Interventional

High Dose IL 2 and Entinostat in RCC

NCT03501381
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Entinostat, Interleukin-2
Drug
Lead sponsor
Roberto Pili
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 19, 2026, 4:19 PM EDT
Terminated Early Phase 1 Interventional

Novel Strategies to Improve Immunomodulation and Non-invasive Clinical Monitoring in VCA

NCT03241719
View directory record Official record
Conditions
Amputation, Traumatic, Amputation;Traumatic;Old, Face Injury, Face; Deformity, Abdominal Wall Defect
Interventions
IL-2
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 19, 2026, 4:19 PM EDT
Active, not recruiting Phase 1 Interventional

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

NCT05704985
View directory record Official record
Conditions
Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer, Gynecologic Cancer, Skin Cancer, Kidney Cancer
Interventions
DK210 (EGFR), Radiation therapy, Immune checkpoint blockers, Chemotherapy
Biological · Radiation · Drug
Lead sponsor
DEKA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Duarte, California • Manhasset, New York • Oklahoma City, Oklahoma + 3 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 19, 2026, 4:19 PM EDT
Completed Phase 1 Interventional

Interleukin-2 in Treating Patients With Myelodysplastic Syndrome

NCT00002746
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
aldesleukin
Biological
Lead sponsor
University of Washington
Other
Eligibility
15 Years to 120 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 19, 2026, 4:19 PM EDT
Completed Phase 2 Interventional Results available

A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma

NCT00211185
View directory record Official record
Conditions
Lymphoma, T-Cell, Peripheral
Interventions
Denileukin diftitox, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Pegfilgrastim
Drug · Other
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
49
States / cities
Birmingham, Alabama • Phoenix, Arizona • Stanford, California + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 19, 2026, 4:19 PM EDT
Terminated Phase 2 Interventional Results available

QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy

NCT03853317
View directory record Official record
Conditions
Merkel Cell Carcinoma
Interventions
Avelumab, N-803, haNK™
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
San Francisco, California • Miami, Florida • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 19, 2026, 4:19 PM EDT
Terminated Phase 1 Interventional

Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer

NCT00005655
View directory record Official record
Conditions
Kidney Neoplasm, Lung Neoplasm, Sarcoma, Breast Neoplasm
Interventions
rh IL-12, rh IL-2
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 19, 2026, 4:19 PM EDT
Completed Phase 1 Interventional

Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine in HIV Positive, Asymptomatic and Symptomatic Individuals

NCT00000664
View directory record Official record
Conditions
HIV Infections
Interventions
Interleukin-2, Polyethylene Glycolated, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2008 · Synced Oct 19, 2026, 4:19 PM EDT
Completed Phase 2 Interventional

Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma

NCT00616564
View directory record Official record
Conditions
Malignant Melanoma
Interventions
GM-CSF
Drug
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
16 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Miami Beach, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 19, 2026, 4:19 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL

NCT05883449
View directory record Official record
Conditions
Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma
Interventions
AFM13, AB-101, Cyclophosphamide, Fludarabine, Interleukin-2
Drug
Lead sponsor
Affimed GmbH
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
15
States / cities
Birmingham, Alabama • Duarte, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 19, 2026, 4:19 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma

NCT00513604
View directory record Official record
Conditions
Melanoma, Malignant Melanoma, Melanoma, Experimental, Experimental Melanomas
Interventions
aldesleukin, therapeutic autologous lymphocytes, Cyclophosphamide, Fludarabine phosphate, Total body irradiation
Biological · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 19, 2026, 4:19 PM EDT
Active, not recruiting Phase 1 Interventional

Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors

NCT05902520
View directory record Official record
Conditions
HNSCC, Melanoma, Gynecologic Cancer, Colorectal Cancer, Lung Cancer, Urogenital Cancer
Interventions
DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2
Biological
Lead sponsor
AgonOx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 19, 2026, 4:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

CCFZ533X2201 - PoC Study in de Novo Renal Transplantation

NCT02217410
View directory record Official record
Conditions
Kidney Transplantation
Interventions
CFZ533, Tacrolimus (Tac), Mycophenolate mofetil (MMF), Corticosteroids (CS), anti-IL2 Induction
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
6
States / cities
Aurora, Colorado • Baltimore, Maryland • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 19, 2026, 4:19 PM EDT
Completed Phase 1Phase 2 Interventional

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer

NCT00019591
View directory record Official record
Conditions
Colorectal Cancer
Interventions
aldesleukin, ras peptide cancer vaccine, adjuvant therapy
Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
2
States / cities
Bethesda, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 19, 2026, 4:19 PM EDT